engleski

DNA ploidy, clinical behavior and 131-I uptake in differentiated thyroid carcinoma

This study was designed to ascertain whether DNA ploidy status effects clinical behavior and 131-I uptake in differentiated thyroid cancer (DTC). DNA ploidy was analyzed by flow ciytometry on the paraffin-embedded tissue from 85 (68 papillary and 17 follicular) DTC. Regional meta had 17/85 (20%) patients (pts), while distant meta had 6/85 (7.1%) pts. Aneuploidy was detected in 28/85 (32.9%) pts (27.9% papillary and 52.9% follicular). Aneuploid DNA content was found in 16.1% pts w/o signs of disease, 76.5% pts with the recurrence or lymph node meta, and in 83.3% pts with distant meta. Follicular ca. pts with meta had also higher (p=0, 037) S-phase fraction compared to the pts w/o meta. Sensitivity of the 131-I whole body scan (WBS) in the detection of the meta was 70%, with 100% specificity and 92% accuracy. False negative 131-I WBS findings were mostly recorded among aneuploid DTC. Therefore, it seems that in DTC aneuploidy correlates with both loss of differentiation and severe prognosis. In conclusion, we propose individualized clinical approach to the pts with aneuploid DTC. As such tumors could become 131-I-ineffective, alternative nuclear medicine diagnostic procedures should be considered in their clinical follow-up.

DNA ploidy; thyroid carcinoma

nije evidentirano